Sheaff Brock Investment Advisors LLC grew its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 3.9% during the 2nd quarter, HoldingsChannel reports. The firm owned 26,263 shares of the biopharmaceutical company’s stock after buying an additional 991 shares during the quarter. Sheaff Brock Investment Advisors LLC’s holdings in Gilead Sciences were worth $1,860,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors also recently added to or reduced their stakes in the company. Archford Capital Strategies LLC purchased a new position in shares of Gilead Sciences during the 1st quarter valued at approximately $106,000. Advisors Preferred LLC purchased a new position in shares of Gilead Sciences during the 1st quarter valued at approximately $140,000. Stelac Advisory Services LLC purchased a new position in shares of Gilead Sciences during the 1st quarter valued at approximately $141,000. Certified Advisory Corp purchased a new position in shares of Gilead Sciences during the 4th quarter valued at approximately $133,000. Finally, Mckinley Capital Management LLC Delaware lifted its position in shares of Gilead Sciences by 67.7% during the 1st quarter. Mckinley Capital Management LLC Delaware now owns 2,130 shares of the biopharmaceutical company’s stock valued at $161,000 after buying an additional 860 shares in the last quarter. Institutional investors and hedge funds own 77.66% of the company’s stock.
Get Gilead Sciences alerts:In other Gilead Sciences news, Director John C. Martin sold 50,000 shares of the firm’s stock in a transaction on Friday, June 1st. The stock was sold at an average price of $68.13, for a total value of $3,406,500.00. Following the completion of the sale, the director now directly owns 3,067,762 shares of the company’s stock, valued at approximately $209,006,625.06. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.30% of the stock is owned by company insiders.
A number of research analysts have recently issued reports on GILD shares. BidaskClub upgraded Gilead Sciences from a “strong sell” rating to a “sell” rating in a research report on Wednesday, June 6th. Zacks Investment Research upgraded Gilead Sciences from a “sell” rating to a “buy” rating and set a $85.00 target price on the stock in a research report on Thursday, April 19th. Barclays decreased their target price on Gilead Sciences from $95.00 to $90.00 and set a “buy” rating on the stock in a research report on Wednesday, May 2nd. Piper Jaffray Companies started coverage on Gilead Sciences in a research report on Wednesday, May 30th. They set a “buy” rating and a $85.00 target price on the stock. Finally, Leerink Swann set a $72.00 target price on Gilead Sciences and gave the company a “market perform” rating in a research report on Wednesday, May 2nd. Twelve investment analysts have rated the stock with a hold rating, fourteen have given a buy rating and two have assigned a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $88.00.
Shares of Gilead Sciences opened at $77.63 on Friday, Marketbeat reports. The company has a debt-to-equity ratio of 1.50, a quick ratio of 3.23 and a current ratio of 3.30. The firm has a market capitalization of $101.29 billion, a price-to-earnings ratio of 9.07, a PEG ratio of -5.94 and a beta of 1.03. Gilead Sciences, Inc. has a fifty-two week low of $64.27 and a fifty-two week high of $89.54.
Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Wednesday, July 25th. The biopharmaceutical company reported $1.91 earnings per share for the quarter, beating analysts’ consensus estimates of $1.56 by $0.35. Gilead Sciences had a return on equity of 41.57% and a net margin of 9.52%. The company had revenue of $5.65 billion for the quarter, compared to analyst estimates of $5.20 billion. During the same quarter last year, the firm posted $2.56 EPS. The firm’s revenue for the quarter was down 20.9% on a year-over-year basis. sell-side analysts expect that Gilead Sciences, Inc. will post 6.56 EPS for the current year.
The business also recently announced a quarterly dividend, which will be paid on Thursday, September 27th. Shareholders of record on Friday, September 14th will be paid a $0.57 dividend. This represents a $2.28 dividend on an annualized basis and a dividend yield of 2.94%. The ex-dividend date is Thursday, September 13th. Gilead Sciences’s dividend payout ratio (DPR) is presently 26.64%.
Gilead Sciences Company Profile
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.
Further Reading: Trading Penny Stocks
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
No comments:
Post a Comment